

**UNITED STATES DISTRICT COURT  
DISTRICT OF NEW JERSEY**

---

ELI LILLY AND COMPANY,	)	
	)	
<i>Plaintiff,</i>	)	
v.	)	
	)	
ACTAVIS ELIZABETH LLC,	)	Civil Action No. 07-3770 (DMC) (MF)
GLENMARK PHARMACEUTICALS	)	
INC., USA, SUN PHARMACEUTICAL	)	
INDUSTRIES LIMITED, SANDOZ INC.,	)	
MYLAN PHARMACEUTICALS INC.,	)	
APOTEX INC., AUROBINDO PHARMA	)	
LTD., TEVA PHARMACEUTICALS	)	
USA, INC., SYNTHON LABORATORIES,	)	
INC., ZYDUS PHARMACEUTICALS,	)	
USA, INC.,	)	
<i>Defendants.</i>	)	
	)	

---

**JOINT STIPULATION TO STAY ACTION BETWEEN ELI LILLY AND  
COMPANY AND ACTAVIS ELIZABETH LLC**

WHEREAS, on September 5, 2007, Plaintiff Eli Lilly and Company (“Lilly”) filed a First Amended Complaint (D.E. 3) against Actavis Elizabeth LLC (“Actavis”), Glenmark Pharmaceuticals, Inc., USA (“Glenmark”), Sun Pharmaceutical Industries Ltd., Sandoz Inc., Mylan Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Teva Pharmaceuticals USA, Inc., Synthon Laboratories, Inc. (“Synthon”), and Zydus Pharmaceuticals USA, Inc. (“Zydus”), Case No. 2:07-CV-03770-DMC-MF, alleging infringement of Lilly’s Patent No. 5,658,590 (“the ‘590 patent”);

WHEREAS, Lilly alleges that Actavis infringed the ‘590 patent by filing of Abbreviated New Drug Application No. 78-940 to obtain approval for the manufacture, use and sale of

atomoxetine hydrochloride capsules in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg dosage forms;

WHEREAS, on September 27, 2007, Actavis filed an Answer (D.E. 10) denying infringement of the '590 patent and raising an affirmative defense that the '590 patent is invalid;

WHEREAS, on December 12, 2007, the Court issued a Consent Judgment and Order (D.E. 105) finally resolving the action between Lilly and Zydus pursuant to a stipulation entered into between those two parties;

WHEREAS, on July 1, 2008, the Court issued a Consent Judgment and Order (D.E. 174) finally resolving the action between Lilly and Glenmark pursuant to a stipulation entered into between those two parties;

WHEREAS, on July 3, 2008, Actavis filed a First Amended Answer (D.E. 177) adding an affirmative defense that the '590 patent is unenforceable due to inequitable conduct;

WHEREAS, on August 21, 2008, the Court endorsed a Stipulation and Order of Dismissal (D.E. 215) dismissing Lilly's claims against Synthon and Synthon's defenses and counterclaims, without prejudice;

WHEREAS, there remain seven defendants including Actavis in the above-captioned action ("the Atomoxetine Action");

WHEREAS, on December 29, 2009, the district court in the Atomoxetine Action granted Lilly's motion for summary judgment of induced infringement of the '590 patent (D.E. 490, 491, 494);

WHEREAS, Lilly and Actavis expect that resolution of the issues in the Atomoxetine Action should resolve all of Lilly's claims against Actavis and Actavis's defenses, with respect to the '590 patent, that were or could have been raised; and

WHEREAS, Lilly and Actavis have agreed to be bound by the judgment on infringement, validity and enforceability of the '590 patent in the Atomoxetine Action to be litigated on the merits to a decision from which no appeal has been or can be taken, and agree that such judgment will be *res judicata* as to Lilly and Actavis,

IT IS HEREBY STIPULATED AND AGREED by the parties, subject to the following and to approval by the Court, through their undersigned attorneys, that further discovery and adjudication of Lilly's claims against Actavis and of Actavis's defenses are hereby stayed in their entirety; and

1. Actavis acknowledges and agrees that the '590 patent would be infringed by manufacture, use, sale, offer to sell, importation or distribution of atomoxetine capsules pursuant to ANDA No. 78-940.

2. Except as provided in paragraph 5 below, all of Lilly's claims against Actavis and Actavis's defenses are stayed until a final court decision from which no appeal has been or can be taken, including any petition for a writ of certiorari to the U.S. Supreme Court or subsequent appeal. Any final appellate ruling or mandate as to infringement and the validity and enforceability of the '590 patent shall be entered in the Atomoxetine Action as if Actavis had fully participated in such appeal.

3. Actavis and Lilly agree to waive any claim against each other for exceptional case, attorneys' fees or costs. Notwithstanding any provision to the contrary in the Atomoxetine

Action, no judgment shall be entered against Actavis or Lilly finding an exceptional case under 35 U.S.C. § 285 or awarding costs or attorneys' fees.


4. To promote the efficient management of preliminary injunction litigation, and notwithstanding any sale, offer to sell, manufacture or importation by any other defendant (or any third party) of an atomoxetine product pursuant to an ANDA, Actavis will notify Lilly ninety (90) days in advance of any sale, offer to sell, manufacture or importation by Actavis (or any third party acting on instructions from or at the direction of Actavis) of an atomoxetine product pursuant to ANDA No. 78-940.

5. In the event that Lilly settles with one or more of the defendants in the Atomoxetine Action prior to entry against Actavis of the final appellate ruling or mandate, Actavis may move and have Lilly's consent, after entry of dismissals in said action or actions, to vacate the stay.

Date: April 19, 2010

Respectfully submitted,  
John F. Brenner /ssp  
By: Laura P. Magurewsky /ssp  
John F. Brenner  
Melissa A. Chuderewicz  
PEPPER HAMILTON LLP  
301 Carnegie Center  
Suite 400  
Princeton, NJ 08543-5276  
Tel: (609) 452-0808  
Fax: (609) 452-1147

*Attorneys for Plaintiff Eli Lilly and Company*

Respectfully submitted,  
  
By: Gregory D. Miller, Esq.  
Podvey, Meanor, Catenacci, Hildner,  
Cocoziello, & Chattman  
One Riverfront Plaza  
Newark, NJ 07102-5497  
Tel: 973-623-1000  
Fax: 973-623-9131

*Attorneys for Defendant Actavis Elizabeth LLC*

*Of Counsel:*

Charles E. Lipsey  
L. Scott Burwell  
Finnegan, Henderson, Farabow,  
Garrett & Dunner, L.L.P.  
Two Freedom Square  
11955 Freedom Drive  
Reston, Virginia 20190-5675  
Tel: (571) 203-2700  
Fax: (202) 408-4400

Robert D. Bajefsky  
Laura P. Masurovsky  
M. Andrew Holtman  
Krista E. Bianco  
Finnegan, Henderson, Farabow  
Garrett & Dunner, L.L.P.  
901 New York Avenue, N.W.  
Washington, D.C. 20001-4413  
Tel: (202) 408-4000  
Fax: (202) 408-4400


Jennifer S. Swan  
Finnegan, Henderson, Farabow  
Garrett & Dunner, L.L.P.  
Stanford Research Park  
3300 Hillview Avenue  
Palo Alto, CA 94304-1203  
Tel: (650) 849-6600  
Fax: (650) 849-6666

*Of Counsel:*

Matthew J. Becker, Esq.  
Jo-Anne Kokoski, Esq.  
Axinn Veltrop & Harkrider LLP  
90 State House Square 11<sup>th</sup> Floor  
Hartford, CT 06103-3704  
Tel: 860-275-8100  
Fax: 860-275-8101

James P. Doyle, Esq.  
Axinn Veltrop & Harkrider LLP  
114 W. 47<sup>th</sup> Street  
New York, NY 10036  
Tel: 212-728-2200  
Fax: 212-728-2201

SO ORDERED, this 19 day of April, 2010.



Dennis M. Cavanaugh  
U.S. District Judge